Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma.
A method based on LC-MS/MS was developed for the determination of the fibrinogen-receptor antagonist Aggrastat in human plasma. The drug is isolated from plasma by liquid extraction and converted into its N-trifluoroacetyl derivative prior to analysis by HPLC with atmospheric pressure negative chemical ionization MS/MS detection. A structural analog is used as the internal standard and the lower quantifiable limit of the assay is 0.4 ng ml-1 with a relative standard deviation of 7%. This assay was used to cross-validate the existing immunoassay by analysis of plasma from patients receiving the drug. The specificity of the immunoassay was thereby confirmed.
Ellis
J D
JD
Department of Drug Metabolism I, Merck Research Laboratories, West Point, PA 19486, USA.
Hand
E L
EL
Gilbert
J D
JD
D002138:Calibration; D002853:Chromatography, Liquid / Q000379:methods; D005343:Fibrinolytic Agents / Q000097:blood*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000097:blood*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011863:Radioimmunoassay; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000097:blood
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban